{
    "clinical_study": {
        "@rank": "127650", 
        "arm_group": [
            {
                "arm_group_label": "lavage  Isobetadine Dermicum solution", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient will receive 1 bladder lavage daily with a  solution of 5ml Isobetadine Dermicum in 100cc saline"
            }, 
            {
                "arm_group_label": "lavage Acetic Acid solution", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline"
            }, 
            {
                "arm_group_label": "lavage with saline", 
                "arm_group_type": "Sham Comparator", 
                "description": "patients will receive during 5 consecutive days a bladder lavage with 100cc saline"
            }, 
            {
                "arm_group_label": "lavage  Urotainer Suby G", 
                "arm_group_type": "Active Comparator", 
                "description": "patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G"
            }
        ], 
        "brief_summary": {
            "textblock": "In patients with advanced multiple sclerosis, permanent urinary catheters are often used to\n      manage the urinary incontinence and bladder emptying problems. These catheters will lead to\n      urinary tract infection, blocking of the catheter etc.. Especially infections with certain\n      bacteria such as proteus, enterobacteriaceae and ESBL producing enterobacteriaceae and\n      pseudomonas can pose a problem for the hospital infection control and for the patient.\n\n      This study wants to evaluate the potential role of regular bladder lavage with saline, a\n      solution of betadine, an acid solution of acetic acid and of URotainer Twin Suby G (\n      Braun)in the decontamination of these bladders and the prevention of clinically relevant\n      urinary tract infections."
        }, 
        "brief_title": "Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Catheter Related Infections", 
        "condition_browse": {
            "mesh_term": [
                "Bacteriuria", 
                "Catheter-Related Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "PAtients will be selected from the catheterised patient population of the National MS Center\n      in Belgium for this prospective randomised comparative pilot studyon bladder lavage.\n\n      The potential benefit for the patient is a reduction in number of clinical urinary tract\n      infections and a reduction of antibiotic use.\n\n      According to the type of bacteria that is cultured from the urine, patients will be\n      allocated to one of 4 subgroups:\n\n        -  30 patients will recieve bladder lavage with a Isobetadine Dermicum Solution\n\n        -  20 patients will revieve bladder lavage with acetic acid solutions\n\n        -  10 patients will recieve bladder lavage with saline\n\n        -  10 patients will receive bladder lavage with Urotainer Suby G\n\n      The effect will be measured by two repeat urine cultures after the bladder lavage( 2days and\n      5 days).\n\n      From a safety perspective and to assess the irritation caused by the lavage, white blood\n      cell counts in the urine will be done.\n\n      Adverse events will be monitored according to GCP regulations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with an indwelling catheter\n\n          -  catheter associated bacteriuria with proteus, enterobacteriaceae or pseudomonas\n\n          -  willing and able to give informed consent to the study\n\n        Exclusion Criteria:\n\n          -  patients with a clinically relevant UTI ( fever, pain or cloudy urine)\n\n          -  cognitively impaired patients\n\n          -  patients not able or willing to give informed consent\n\n          -  patients with allergies for ISobetadine dermicum or other substances used in the\n             protocol\n\n          -  patients who only have a catheter for less than 1 month\n\n          -  patients taking systemic antibiotics during the last 48h"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772875", 
            "org_study_id": "BLLAV-1"
        }, 
        "intervention": {
            "arm_group_label": [
                "lavage  Isobetadine Dermicum solution", 
                "lavage Acetic Acid solution", 
                "lavage with saline", 
                "lavage  Urotainer Suby G"
            ], 
            "description": "the bladder is rinced through the urinary catheter with the lavage solution", 
            "intervention_name": "bladder lavage", 
            "intervention_type": "Procedure", 
            "other_name": "bladder rincing"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "urinary catheter", 
            "UTI", 
            "bladder lavage"
        ], 
        "lastchanged_date": "January 18, 2013", 
        "link": {
            "description": "website of the National MS Center, Belgium", 
            "url": "http://www.mscenter.be"
        }, 
        "location": {
            "contact": {
                "email": "dirk.deridder@uzleuven.be", 
                "last_name": "Dirk De Ridder, Prof."
            }, 
            "contact_backup": {
                "email": "corinne.cuvelier@mscenter.be", 
                "last_name": "Corinne Cuvelier, RN"
            }, 
            "facility": {
                "address": {
                    "city": "Steenokkerzeel", 
                    "country": "Belgium", 
                    "state": "Vlaams-Brabant", 
                    "zip": "1820"
                }, 
                "name": "National MS Center"
            }, 
            "investigator": {
                "last_name": "Dirk De Ridder, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "4", 
        "official_title": "Pilot Study to Evaluate the Efficacy of Antiseptic Bladder Lavage Versus Pulsatile Lavage With Physiologic Serum in Catheterized Patients With Asymptomatic Bacteriuria With Uropathogens.", 
        "overall_contact": {
            "email": "dirk.deridder@uzleuven.be", 
            "last_name": "Dirk De Ridder, PRof.", 
            "phone": "+32-16-346930"
        }, 
        "overall_contact_backup": {
            "email": "corinne.cuveliers@mscenter.be", 
            "last_name": "Corinne Cuveliers, RN", 
            "phone": "+32-2-5978801"
        }, 
        "overall_official": {
            "affiliation": "National MS Center Belgium & University Hospitals KU Leuven", 
            "last_name": "Dirk De Ridder, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "After 5 consecutive days of bladder lavage, a urine culture will be taken at day 2 and 5. A count of <100.000 CFU/ml and is considered a positive result.\nThe outcome will be considered positive if this positive result is found in more than 30% of subjects.", 
            "measure": "urinary culture", 
            "safety_issue": "No", 
            "time_frame": "day 2 and day 5 after last bladder lavage"
        }, 
        "reference": {
            "PMID": "23205350", 
            "citation": "Jaggi N, Sissodia P. Multimodal supervision programme to reduce catheter associated urinary tract infections and its analysis to enable focus on labour and cost effective infection control measures in a tertiary care hospital in India. J Clin Diagn Res. 2012 Oct;6(8):1372-6. doi: 10.7860/JCDR/2012/4229.2362."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772875"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Multiple Sclerosis Center", 
            "investigator_full_name": "Prof. dr. Dirk De Ridder", 
            "investigator_title": "medical director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "changes in white blood cell count are monitored at day 2 and 5 afte 5 consecutive days of bladder lavage. This is an assessment of bladder irritation.", 
            "measure": "pyuria", 
            "safety_issue": "Yes", 
            "time_frame": "day 2 and day 5 after the last bladder lavage"
        }, 
        "source": "National Multiple Sclerosis Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Multiple Sclerosis Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}